ACM derived from OGJ patients with early-stage tumours and late-stage tumours significantly increased the frequency of Th17-like CD4+ cells (untrx: 5.07 ± 0.2 vs. early-stage: 7.14 ± 0.7%, p = 0.01, and late-stage: 6.37 ± 0.5%, p = 0.05) and the frequency of Th1/17-like CD4+ T cells (untrx: 14.07 ± 0.2 vs. early-stage: 16.15 ± 0.9%, p = 0.02, and late-stage: 15.19 ± 0.6%, p = 0.007) compared with untreated cells (Fig. 4A). The gene discussed is CD4; the disease is neoplasm.